At CTAD 2023, the scientific program will again focus on bringing thought-provoking roundtable and symposia on the latest advances in AD clinical research, bringing together renowned clinicians and leaders from key research centers, academia, patient coalition and pharmaceutical companies.

CTAD is also committed to exploring new avenues beyond amyloid-clearing treatments including disease-modifying agents, gene therapy, vaccines and multimodal interventions.

The CTAD scientific program is based on a strict peer-review abstract selection process. CTAD 2023 is a great opportunity for clinical teams around the world to showcase their work in AD clinical trials.